Adding dapagliflozin to standard care improves outcomes for people with heart failure and reduced ejection fraction irrespective of sex, suggests a prespecified subgroup analysis of the DAPA-HF trial.
Post-hoc analysis of the primary prevention subgroup of DECLARE-TIMI 58 suggests that treatment with dapagliflozin may reduce the risk for first heart failure and renal events.
The SGLT2 inhibitor canagliflozin reduces blood pressure and the need for additional antihypertensives in people with type 2 diabetes and chronic kidney disease, research suggests.